Outpatient Pain Therapy
SKU:
$1,190.00
$1,190.00
per item
Description
Oral analgesics, Chronic pain patients, Intravenous analgesics, Subcutaneous analgesics
In Germany, around 15 million people suffer from chronic pain. The predominant part is treated with oral painkillers (analgesics). Intravenous pain therapy is predominantly used in palliative care situations or in very severe chronic pain conditions. Cancer is the most common indication for ambulatory intravenous pain therapy.
The Qnidos Deutsche Health Intelligence Study "Ambulatory Pain Therapy" provides executives of care providers, manufacturers and cost takers with a comprehensive insight into current and future market conditions. The focus of the market investigation is on the detailed presentation of the competitive situation of service providers and their market shares.
In addition, the report provides an overview of the disease pictures relevant to this indication and their distribution, as well as the number of patients who are acutely affected by this form of care.
In addition to a detailed growth forecast for the next five years, the study answers the following questions on outpatient pain therapy:
When is intravenous / subcutaneous ambulatory pain therapy used?
How has the market volume in the reimbursement market for outpatient pain therapy developed?
How will the reimbursement rates develop?
How many pain therapies exist in Germany and how many patients are provided there per quarter?
What reimbursement conditions are there?
In Germany, around 15 million people suffer from chronic pain. The predominant part is treated with oral painkillers (analgesics). Intravenous pain therapy is predominantly used in palliative care situations or in very severe chronic pain conditions. Cancer is the most common indication for ambulatory intravenous pain therapy.
The Qnidos Deutsche Health Intelligence Study "Ambulatory Pain Therapy" provides executives of care providers, manufacturers and cost takers with a comprehensive insight into current and future market conditions. The focus of the market investigation is on the detailed presentation of the competitive situation of service providers and their market shares.
In addition, the report provides an overview of the disease pictures relevant to this indication and their distribution, as well as the number of patients who are acutely affected by this form of care.
In addition to a detailed growth forecast for the next five years, the study answers the following questions on outpatient pain therapy:
When is intravenous / subcutaneous ambulatory pain therapy used?
How has the market volume in the reimbursement market for outpatient pain therapy developed?
How will the reimbursement rates develop?
How many pain therapies exist in Germany and how many patients are provided there per quarter?
What reimbursement conditions are there?
